Quarterly Results

202602 Results Summary

Revenue

The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Operating Profit

Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

PBDT

PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Profit Before Tax

Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Net Profit

Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Company News

More

Earnings

CategoryQ3 FY25-26Q3 FY24-25Change %FY24-25FY23-24Change %
Total Revenue8,645.907,978.528.3631,723.7329,001.879.39
Expenses6,937.896,400.548.4025,172.6323,367.897.72
Other Income188.01158.8818.33621.85557.3811.57
Operating Profit280.78277.361.237,172.956,191.3615.85
Depreciation464.73418.5311.041,649.421,521.668.40
Interest92.77118.48-21.70457.24289.7157.83
Profit Before Tax1,338.521,199.8511.565,066.294,379.9915.67
Tax428.72354.2821.011,699.981,777.54-4.36
Net Profit975.62845.8115.353,483.573,168.979.93
CategoryQ3 FY25-26Q2 FY25-26Change %
Total Revenue8,645.908,285.704.35
Expenses6,937.896,607.605.00
Other Income188.01122.2553.79
Operating Profit280.78217.4929.10
Depreciation464.73429.198.28
Interest92.7795.24-2.59
Profit Before Tax1,338.521,275.924.91
Tax428.72427.790.22
Net Profit975.62848.4514.99

Research Reports

ActionTarget Price (₹)BrokerDateReports
Data Not Found

Financial Reports

Data not available.

Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Data Not Found

Corporate Information

Company News

Motilal Oswal retains 'Buy' on Aurobindo Pharma as FY26-28 prospects shine

Tushar Manudhane, Vipul Mehta, and Eshita Jain, research analysts at MOFSL, value Aurobindo Pharma at 16 times 12-month forward earnings, assigning a target price of ₹1,430

Updated On: 04 Dec 2025 | 9:25 AM IST

Sun Pharma sees Golden Cross; other pharma stocks with similar pattern

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

Updated On: 26 Nov 2025 | 10:57 AM IST

Nifty, Bank Nifty outlook; Shriram Fin, Ashok Leyland among top stock picks

On the daily chart, Nifty formed a bearish candle and continues to maintain a sequence of lower highs and lower lows for the fourth straight session indicating sustained pressure

Updated On: 26 Nov 2025 | 7:50 AM IST

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Updated On: 25 Nov 2025 | 7:59 AM IST

Stocks to Watch today, Nov 24: HUL, TCS, RVNL, HG Infra, Marico

Stocks to Watch today, November 24, 2025: From RVNL to HUL, here is a list of stocks that will be on investors' and traders' radar

Updated On: 24 Nov 2025 | 7:52 AM IST

Q2FY26 results in line; Aurobindo Pharma could gain 25%, says Nuvama

According to Nuvama, Aurobindo's Q2FY26 revenue and Ebitda were ahead of consensus estimates by 2 per cent and 1 per cent, respectively, though PAT missed expectations by about 5 per cent

Updated On: 07 Nov 2025 | 8:29 AM IST

Tariff relief buzz lifts Nifty Pharma Index; Lupin, Aurobindo lead gains

Pharma stocks were rising in trade today as export concerns eased on US tariff report. Check out the top stocks that may benefit from US tariff relief

Updated On: 09 Oct 2025 | 11:02 AM IST

Pfizer soars 8%; Sun, Lupin gain up to 4%; here's what triggered the rally

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.

Updated On: 01 Oct 2025 | 9:59 AM IST

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Updated On: 26 Sep 2025 | 9:13 AM IST

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Updated On: 26 Sep 2025 | 10:08 AM IST
More